跳至主要内容
临床试验/NCT06538987
NCT06538987已完成不适用

Anesthetic Management in Patients Undergoing Epicardial Ablation for the Treatment of Ventricular Tachycardia; Retrospective Study

Eskisehir Osmangazi University1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2024年8月30日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
22
试验地点
1
主要终点
sex

研究概览

简要总结

The study is a retrospective study and is descriptive in nature. In this study, the investigators aimed to emphasize the importance of anesthesia management by cardiac risk assessment of patients undergoing epicardial ablation under general anesthesia and analysis of complications that developed during the procedure.

详细描述

The study is retrospective observational and data were collected by examining the files of all epicardial ablation patients received in the angiography unit starting from 30.10.2020 until 30.10.2022 after ethics committee approval is obtained. Baseline characteristic features of the patients Sex, Age, (years, BMI (kg/m2) Hypertension, Coronary artery disease, COPD (Chronic obstructive pulmonary disease), CKD (Chronic kidney disease) Electrical storm, and ventricular tachycardia etiology, Ischemic cardiomyopathy, Dilated cardiomyopathy, the presence of ARVC (Arrhythmogenic Right Ventricular Cardiomyopathy), Hypertrophic cardiomyopathy will be recorded. NHYA classification will be examined in two groups as NHYA I or II and NHYA III or IV, also estimated glomerular filtration rate, left ventricular ejection fraction, PAAINESD (acute hemodynamic decompensation risk assessment score), iVT score (Risk of VT recurrence) Score information will be recorded. Ventricular tachycardia focus locations, dopamine, dobutamine, norepinephrine infusion requirement during the procedure, arrest development during the procedure, fluoroscopy time and ablation times will be recorded. In the follow-up of the patients after the procedure Causes of death, decompensated heart failure, transient ischemic attack, development of acute renal failure, and recurrence of ventricular tachycardia will be recorded. PAAINESD score (acute hemodynamic decompensation risk assessment score) will be recorded. The PAAINESD Score, developed to estimate the risk of periprocedural hemodynamic decompensation, has values ranging from 0 to 35 points (or 0 to 31 [PAINESD] when the modifiable intraprocedural variable "general anesthesia" is excluded). duration of the procedure, the need for inotropes during the procedure, whether the patient needed mechanical ventilation after the procedure, and the success rates after the procedure will be recorded.

PAINESD Pulmonary disease (chronic obstructive pulmonary disease) 5 Age >60 years 3 Anaesthesia (general) 4 Ischaemic cardiomyopathy 6 NYHA class III or IV 6 Ejection fraction <25 % 3 Storm (VT). 5 Diabetes 3 Data will be analyzed in three separate categories, the characteristics of the patients before the procedure, during the procedure and after the procedure. Descriptive tables and percentages of parameters will be created by statistical analysis.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age > 18 years old who underwent elective VT ablation between 2020 - 2022,
  • primary anesthetic type listed as general anesthesia

排除标准

  • age < 18 years,
  • missing follow-up data,
  • patients who have previously undergone epicardial ablation

结局指标

主要结局

sex

时间窗: 2 years

male %

age

时间窗: 2 years

years

weight

时间窗: 2 years

kilograms

height

时间窗: 2 years

meters

Hypertension

时间窗: 2 years

yes or no

Diabetes mellitus

时间窗: 2 years

yes or no

Coronary artery disease

时间窗: 2 years

yes or no

Chronic obstructive pulmonary disease

时间窗: 2 years

yes or no

Chronic kidney disease

时间窗: 2 years

yes or no

Systolic pulmonary artery pressure

时间窗: 2 years

mmHg

Left ventricular ejection

时间窗: 2 years

%

PAAINESD (Acute hemodynamic decompensation risk assessment, ranging from 0 to 35 points, 35 point is the worst) score

时间窗: 2 years

score 0-35

ASA ( American Society of Anesthesiologists (ASA) physical status classification ranging from I to IV

时间窗: 2 years

score I-IV

Hemoglobin

时间窗: 2 years

g/dl

glomerular filtration rate (eGFR)

时间窗: 2 years

ml/dak/1,73m2

Total procedural time

时间窗: 2 years

minutes

Fluoroscopy time

时间窗: 2 years

minutes

Ablation time

时间窗: 2 years

minutes

次要结局

  • Transient ischemic attack after procedure(2 years)
  • Exitus during the follow-up(2 years)
  • cause of death(2 years)

研究者

发起方
Eskisehir Osmangazi University
申办方类型
Other
责任方
Principal Investigator
主要研究者

Ferda YAMAN

Associate Professor

Eskisehir Osmangazi University

研究点 (1)

Loading locations...

相似试验

Anesthetic Management in Patients Undergoing... | 临床试验